Scholar Rock hits 3-month high as its drug helped preserve muscle in overweight patients

Shares of drug developer Scholar Rock Holding Corp SRRK.O gain 17.7% to a three-month high of $36.68

Stock set to have its best day since Nov 2024, if gains hold

Co says its experimental drug helped patients with obesity preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's LLY.N weight-loss treatment Zepbound

Patients receiving co's drug apitegromab with LLY's drug showed a 54.9% preservation of lean mass versus Zepbound alone over 24 weeks

Patients receiving the combination lost more fat mass than those on LLY's tirzepatide alone

Up to last close, stock down ~28% YTD